ArticleEuropean journal of medical research2025
Novel inflammation biomarkers in adult minimal change disease: predicting steroid-resistance and relapse.
Article in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
introductionThe novel systemic inflammation markers are a class of indicators combining clinically common laboratory indices, reflecting the underlying immune and inflammatory status. Minimal change disease (MCD) is an important cause of idiopathic nephrotic syndrome (INS) in adults. Novel systemic inflammation markers were evaluated for their ability to predict treatment response to steroids and subsequent relapse in adult-onset MCD.
methodsThis unicentric, retrospective study included the clinical data of adult-onset INS patients who were pathologically diagnosed with MCD at Xiangya Hospital of Central South University from January 2010 to December 2021 and followed up with the patients' remission after adequate steroid treatment, starting from the time of initial complete remission to May 31, 2022, with recurrence as the end-point event. Eight common and associated novel systemic inflammation markers were collected, and univariate analysis of these markers was performed using dummy variable assignment or maximally selected rank statistics. Multivariate logistic regression and Cox regression statistics identified the independent risk factors for steroid resistance and relapse after initial remission in adult-onset MCD, respectively.
resultsA total of 121 patients were included; the median age was 22 (19,40) years, and there were 92 (76%) men. Adequate corticosteroids were the initial treatment: 98 (81%) patients achieved remission, and 23 (19%) developed steroid resistance. Of the 98 patients with remission, the median age was 25 (19, 44) years, 76 (77.6%) were male, the median follow-up time was 11.4 (6.3, 33.4) months, and 46 (46.9%) experienced relapse. The multivariate analysis showed that elevated C-reactive protein to albumin ratio (CAR) (≥ 0.196) and derived neutrophil/ (leukocyte minus neutrophil) ratio (dNLR) (≥ 1.32) were independent predictors of steroid resistance and relapse in adult-onset MCD, respectively.
conclusionsThe novel systemic inflammation markers CAR and dNLR may play significant roles in steroid treatment and the prognosis of MCD in adults, and deeper clinical studies in the future are warranted.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.